Evolving post-Covid-19 | Patient and provider perspectives informing pharma implications

Yasasvi Popuri, Jay Lichtenstein, Catherine Pagano, Sean Sinisgalli, Ganesh Vedarajan and Rishi Upadhyaya

In April 2020, ZS surveyed 388 physicians, nearly 500 patients and ~ 30 hospital administrators for a pulse of COVID-19 implications. The results highlight what pharma companies should do next, including:

  • Managing disruption to care
  • Perspectives on the new normal
  • The evolving role of pharma